Navigation Links
Dendreon Reports Fourth Quarter and 2007 Year End Financial Results
Date:3/13/2008

- Dendreon to Hold Conference Call Today, March 13, 2008 at 11:00 AM ET -

SEATTLE, March 13 /PRNewswire-FirstCall/ -- Dendreon Corporation (Nasdaq: DNDN) today reported results for the year and quarter ended December 31, 2007. Revenues for the year ended December 31, 2007 were $743,000 compared to $273,000 for the year ended December 31, 2006. Revenues for the fourth quarter of 2007 were $28,000, compared to $86,000 for the same period in 2006.

The net loss for the year ended December 31, 2007 was $99.3 million, or $1.20 per share, compared to $91.6 million, or $1.27 per share for the year ended December 31, 2006. Net loss in the fourth quarter of 2007 was $27.0 million or $0.32 per share, compared to a net loss of $21.5 million, or $0.28 per share, for the same period in 2006. Dendreon's total operating expenses for the year ended December 31, 2007 were $102.4 million compared to $97.6 million in 2006. Net cash used in operating activities in 2007 was $82.6 million compared to $80.8 million in 2006.

As of December 31, 2007, Dendreon had approximately $120.6 million in cash, cash equivalents, and short-term and long-term investments compared to $121.3 million as of December 31, 2006.

Recent Highlights:

-- The FDA agreed to amend the IMPACT (IMmunotherapy for Prostate

AdenoCarcinoma Treatment) Special Protocol Assessment (SPA),

accelerating the expected timeline for final results from the study by

approximately one year while maintaining comparable power to the

previous SPA. In addition, the FDA reconfirmed that either a positive

interim or final analysis of survival would support licensure and

enable Dendreon to amend the company's biologic
'/>"/>

SOURCE Dendreon Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Dendreon Announces Webcast Presentation at UBS Life Sciences Conference
3. Dendreon Secures $130 Million Committed Equity Financing Facility
4. Dendreon Announces Webcast Presentations at Upcoming Investor Conferences
5. Dendreon Reports Third Quarter 2007 Financial Results
6. Dendreon Promotes Dr. Mark Frohlich to Senior Vice President of Clinical Affairs and Chief Medical Officer
7. Dendreon Announces Webcast Presentation at BIO CEO & Investor Conference
8. Dendreon Publishes Manuscript on CD54 as a Surrogate Marker of Antigen Presenting Cell Activation
9. -Dendreon to Hold Conference Call on Thursday, March 13, 2008 at 11:00 AM ET-
10. FDA Agrees to Amend Dendreons Special Protocol Assessment for Phase 3 IMPACT Study of PROVENGE
11. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... , ... September 02, 2015 , ... ... improve efficiency of their entire waste to energy process and continue to contribute ... a Major Upgrade , Temarry’s Waste to Energy process has been operating at ...
(Date:9/1/2015)... The American Brain Tumor Association (ABTA) is now accepting ... program. LOIs are due no later than Wednesday, October ... Discovery Grants are one-year, $50,000 grants that fund high risk/high ... or treatment paradigms for adults and children with brain ... earliest stages, in the hopes that it spurs additional ...
(Date:9/1/2015)... ... September 01, 2015 , ... AxioMx ... that the National Institutes of Health (NIH) has awarded the company a Phase ... the NIH’s National Institute of Diabetes and Digestive and Kidney Diseases. AxioMx will ...
(Date:9/1/2015)... 2015   Medfusion, Inc., a patient ... doctors and patients, today announced a $3 million ... -based venture capital firms.   "We ... Bull City Venture Partners and Hatteras Venture Partners," ... Executive Chairman. "Both firms, experience working at the ...
Breaking Biology Technology:Temarry Recycling’s New $100,000 Waste to Energy Renovation 2American Brain Tumor Association Seeks Innovative Concepts For Discovery Research Grants 2AxioMx Announces Receipt of SBIR Grant for DNA-Protein Complex Antigen Development 2AxioMx Announces Receipt of SBIR Grant for DNA-Protein Complex Antigen Development 3Medfusion Secures Funding to Continue Evolution and Advance Mobile Strategy 2Medfusion Secures Funding to Continue Evolution and Advance Mobile Strategy 3
... October 5 , - A New Miniaturized PCR ... Price of QuanTyper(TM) Without Loss of Performance, - ... AlphaHelix (Ticker: ALPH) has in a very ... for lower,instrument prices. This was made possible through know-how obtained during,the ...
... Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM ) today reported ... bavituximab in combination with carboplatin and paclitaxel in patients ... reported from the initial cohort of 21 patients in ... patients with locally advanced or metastatic NSCLC achieved an ...
... ... Global packaging specialist,Sepha, says the increased pressure to reduce costs and ... and blister-scanning technologies. While blisterpacks offer pharmaceutical companies a simple ... often makes it difficult to either test for leaks or recover ...
Cached Biology Technology:AlphaHelix Presents AmpXpress(TM) at the BIOTECHNICA Show 2Peregrine Pharmaceuticals Reports Positive Results From Phase II Bavituximab Lung Cancer Trial 2Peregrine Pharmaceuticals Reports Positive Results From Phase II Bavituximab Lung Cancer Trial 3Peregrine Pharmaceuticals Reports Positive Results From Phase II Bavituximab Lung Cancer Trial 4Environmental & Economic Factors Drives Global Demand for Pharmaceutical leak Testing and Deblistering 2Environmental & Economic Factors Drives Global Demand for Pharmaceutical leak Testing and Deblistering 3
(Date:8/12/2015)... 12, 2015 As the digital ... innovation and advanced biometrics technology is accelerating beyond expectations.  ... rely on using their credit cards, the digital currency, ... for payment services led by companies in the space ... Google, Inc. (NASDAQ: GOOG ), Apple Inc. (NASDAQ: ...
(Date:8/12/2015)... SAN JOSE, Calif. , Aug. 12, 2015 ... leading developer of human interface solutions, today announced ... the recently announced Match-in-Sensor solution, have officially been ... (FIDO) Alliance. As part of the certification, Synaptics, ... the FIDO 1.0 Universal Authentication Framework (UAF) standard ...
(Date:8/10/2015)... Germany , August 10, 2015 ... in Eye Tracking Technology for more than two decades, ... Platform for integration into all consumer display formats. The ... seamless integration of eye tracking into consumer tablets, laptops, ... reality smart glasses. Omnivision,s leading sensor technology contributes to ...
Breaking Biology News(10 mins):Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 2Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 3Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 4Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 5Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 6Synaptics Announces FIDO Certification of Natural ID Fingerprint Solutions 2Synaptics Announces FIDO Certification of Natural ID Fingerprint Solutions 3SMI Completes OEM Eye Tracking Platform to Cover All Consumer Displays 2SMI Completes OEM Eye Tracking Platform to Cover All Consumer Displays 3
... LyondellBasell announced the following schedule and contact information for a teleconference on financial results through the ... , Monday, August 16, 2010 , ... Doug Pike, Vice President, Investor Relations , ... 800-369-1176 , London: 0800-279-9630 , ...
... Georgia Institute of Technology are using funding from the ... as ARPA-E to pursue two different, but related, ... of coal-burning power plants. Power plants ... the United States each year. The researchers will ...
... URBANA A dog,s indiscriminate taste is not always ... gastrointestinal infections and consequent ailments such as diarrhea and ... gastrointestinal diseases such as inflammatory bowel diseases that are ... by intestinal bacteria. Researchers at the University ...
Cached Biology News:Teleconference Alert: LyondellBasell Reviews Second Quarter 2010 Financial Results 2ARPA-E funding supports research on carbon dioxide removal from flue gases 2ARPA-E funding supports research on carbon dioxide removal from flue gases 3ARPA-E funding supports research on carbon dioxide removal from flue gases 4Illinois researchers use pyrosequencing to study canine intestinal bacteria 2
PlusOne EDTA, disodium salt, 100 g. Category: Electrophoresis Systems & Standards & Reagents, Electrophoresis Standards and Reagents, Buffers....
Normal human serum collected off the clot from healthy normal humans. Each donor unit is negative for anti-HIV 1&2, HIV-Ag, HCV, and HBsAg by FDA required tests...
sterile filtered, off the clot, all male donors, Total Protein: 4.5 to 8.5 g/dl...
Recombinant Mouse MMP-9, CF...
Biology Products: